Skip to main content
. 2019 Jun 11;17:197. doi: 10.1186/s12967-019-1949-5

Table 1.

General data of the AAV patients

Parameters Value
Number 34
Gender (male/female) 12/22
Age at diagnosis 61.7 ± 11.9
MPO-ANCA/PR3-ANCA 30/4
ESR (mm/1 h) 65.8 ± 39.2
Scr (μmol/L) 266.9 (196.3–410.0)
Proteinuria (g/24 h) 1.42 ± 1.25
Clinical manifestation
 Skin rash 5 (14.7%)
 Arthralgia 3 (8.8%)
 Muscle pain 5 (14.7%)
 Pulmonary 18 (52.9%)
 ENT 10 (29.4%)
 Ophthalmic 10 (29.4%)
 Gastrointestinal 3 (8.8%)
 Nervous 5 (14.7%)
BVAS 18.6 ± 5.2
Glomeruli per biopsy 30.0 ± 13.8
Glomerular lesions (%)
 Total crescents 62.2 ± 21.0
 Fibrinoid necrosis 1.3 (0–6.6)
 Glomerulosclerosis 2.7 (0–10.0)
Tubulointerstitial lesions
 Tubular atrophy (−/+/++) 5/25/4
 Interstitial infiltration (−/+/++/+++ ) 0/8/21/5
 Interstitial fibrosis (−/+/++) 3/25/6
Berden classification n (%)
 Focal 5 (14.7)
 Crescentic 24 (70.6)
 Mixed 5 (14.7)
 Sclerotic 0 (0)

Statistics are shown as mean ± standard deviation or median (IQR) for different distributions

ESR erythrocyte sedimentation rate, Scr serum creatinine, ENT ear, nose and throat, BVAS Birmingham Vasculitis Activity Score